Haemophilia

Cover image for Haemophilia

March 2002

Volume 8, Issue Supplement s2

Pages 1–67

  1. Original Articles

    1. Top of page
    2. Original Articles
    1. Manufacturing challenges in the commercial production of recombinant coagulation factor VIII (pages 1–5)

      R. Jiang, T. Monroe, R. Mcrogers and P. J. Larson

      Version of Record online: 23 NOV 2002 | DOI: 10.1046/j.1351-8216.2001.00115.x

    2. Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE® Bayer (pages 6–9)

      D. C. Lee, J. L. A. Miller and S. R. Petteway JR

      Version of Record online: 23 NOV 2002 | DOI: 10.1046/j.1351-8216.2001.00117.x

    3. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients (pages 10–14)

      C. Rothschild, I. Scharrer, H.-H. Brackmann, N. Stieltjes, M. Vicariot, M.-F. Torchet and W. Effenberger

      Version of Record online: 23 NOV 2002 | DOI: 10.1046/j.1351-8216.2001.00131.x

    4. Experience with KOGENATE® Bayer in surgical procedures (pages 15–18)

      I. Scharrer and THE KOGENATE® Bayer Study Group

      Version of Record online: 23 NOV 2002 | DOI: 10.1046/j.1351-8216.2001.00132.x

    5. Inhibitor development in correlation to factor VIII genotypes (pages 23–29)

      J. Oldenburg, O. El-Maarri and R. Schwaab

      Version of Record online: 23 NOV 2002 | DOI: 10.1046/j.1351-8216.2001.00134.x

    6. Comparative pharmacokinetic studies in haemophilia (pages 30–33)

      M. Morfini

      Version of Record online: 23 NOV 2002 | DOI: 10.1046/j.1351-8216.2002.00136.x

    7. Aspects of haemophilia prophylaxis in Sweden (pages 34–37)

      R. C. R. Ljung

      Version of Record online: 23 NOV 2002 | DOI: 10.1046/j.1351-8216.2001.00118.x

    8. Results of an orthopaedic survey in young patients with severe haemophilia in Spain (pages 38–42)

      J. M. Tusell, J. A. Aznar, F. Querol, M. Quintana, M. Moreno, E. Gorina and THE ORTHOPAEDIC STUDY GROUP

      Version of Record online: 23 NOV 2002 | DOI: 10.1046/j.1351-8216.2001.00119.x

    9. Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies (pages 43–46)

      H. M. Van Den Berg, K. Fischer, J. G. Van Der Bom, G. Roosendaal and E. P. Mauser-Bunschoten

      Version of Record online: 23 NOV 2002 | DOI: 10.1046/j.1351-8216.2001.00120.x

    10. Pilot testing of the ‘Haemo-QoL’ quality of life questionnaire for haemophiliac children in six European countries (pages 47–54)

      M. Bullinger, S. Von Mackensen, K. Fischer, K. Khair, C. Petersen, U. Ravens-Sieberer, A. Rocino, P. Sagnier, J. M. Tusell, M. Van Den Berg and M. Vicariot

      Version of Record online: 23 NOV 2002 | DOI: 10.1046/j.1351-8216.2001.114.doc.x

    11. The concept of idiotypic vaccination against factor VIII inhibitors in haemophilia A (pages 55–59)

      S. Lacroix-Desmazes, J. Bayry, N. Misra, S. V. Kaveri and M. D. Kazatchkine

      Version of Record online: 23 NOV 2002 | DOI: 10.1046/j.1351-8216.2001.00116.x

    12. Parvovirus-mediated gene transfer for the haemophilias (pages 60–67)

      C. E. Walsh and H. Chao

      Version of Record online: 23 NOV 2002 | DOI: 10.1046/j.1351-8216.2001.00121.x

SEARCH

SEARCH BY CITATION